Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Quality-Of-Life Data Favor Stenting Over Drugs In Short-Term

This article was originally published in The Pink Sheet Daily

Executive Summary

The high-profile COURAGE trial again raises the question of how soon stents should be placed in patients with coronary disease.

You may also be interested in...



Study Shows No Death, MI Advantages For Stenting Over Medical Therapy

Results form the 2,287-patient COURAGE trial presented the American College of Cardiology meeting should give physicians more to think about before moving forward with percutaneous coronary intervention in stable heart disease patients, researchers say.

Feds Try To Pave Path For Frustrated Pediatric Device Innovators

NIH and government agencies plan to submit plans to Congress next month describing ways to encourage the development of medical devices for children.

Legal Issues Abound For Device Marketers In The Blogosphere

Do not be cavalier about this venue, drug/device lawyer warns.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS068228

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel